<DOC>
	<DOCNO>NCT00806663</DOCNO>
	<brief_summary>This open label single arm prospective multicenter Phase II study around 20 patient . The primary objective study evaluate whether addition sunitinib FOLFIRI result significant reduction tumor vessel permeability ( TVP ) blood flow ( BF ) measure DCE-MRI DCE-USI , measure liver metastasis . Secondary objective antitumor response , time progression ( TTP ) , effect pharmacokinetics sunitinib biomarkers ( VEGF und soluble VEGF-receptor ) drug/treatment safety .</brief_summary>
	<brief_title>FOLFIRI Sunitinib Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Adult male female : 18 year age . Patients histologically cytologically confirm colorectal cancer receive first palliative treatment . Patients least one measurable hepatic lesion 2 cm accord RECIST criterion . ECOG 0 1 . Signed write informed consent . White blood cell count ( WBC ) &gt; = 4x10^9/L neutrophil &gt; = 1.5 x 10*9/L , platelet count &gt; = 100x10*9/L , hemoglobin &gt; = 5.6 mmol/L ( 10 g/dL ) . Total bilirubin = &lt; 2 x upper limit normal . AST ALT = &lt; 2.5 x upper limit normal , = &lt; 5 x upper limit normal case liver metastasis . Serum creatinine = &lt; 1.5 x upper limit normal creatinine clearance &gt; 60 ml/min Normal ECG without QT prolongation . Resectable liver metastasis . Adjuvant therapy FOLFOX 5FU / Capecitabine = &lt; 6 month prior treatment study previous palliative chemotherapy.. Any contraindication FOLFIRI chemotherapy regimen . Any investigational drug within 30 day inclusion . Prior use sunitinib multitarget tyrosine kinase inhibitor VEGF pathway direct treatment like bevacizumab . Known suspected allergy hypersensitivity reaction component study treatment . Pregnancy ( absence confirm betahCG test ) lactation period Men woman childbearing potential sexually active unwilling use medically acceptable method contraception trial Clinically symptomatic brain meningeal metastasis . ( know suspect ) Cardiac arrhythmia require antiarhythmics ( exclude beta blocker digoxin ) . History follow cardiac event within past 6 month : myocardial infarction ( include severe/ unstable angina ) , coronary/peripheral artery bypass graft , congestive heart failure ( CHF ) , cerebrovascular accident , transient ischemic attack pulmonary embolism . History clinically significant bleeding within past 6 month , include gross hemoptysis haematuria , underlie coagulopathy . History peptic ulcer disease , deep vein thrombosis , significant thromboembolic event within past 6 month . Uncontrolled severe hypertension ( failure diastolic blood pressure fall 90 mm Hg despite use &gt; = 3 antihypertensive drug . Acute subacute intestinal occlusion history inflammatory bowel disease chronic diarrhea . Previous malignancy ( colorectal cancer ) last 5 year except basal cell cancer skin , preinvasive cancer cervix superficial bladder tumor [ Ta , Tis T1 ] . History organ allograft Treatment potent CYP3A4 inhibitor within 7 day sunitinib/placebo dose potent CYP3A4 inducer within 12 day sunitinib/placebo dose . Prior full field radiotherapy = &lt; 4 week , limited field radiotherapy , = &lt; 2 week prior study enrollment ; previous radiation treatment &gt; 30 % bone marrow . Major surgical procedure , open biopsy significant traumatic injury within 4 week start treatment ; anticipation need major surgical procedure ( e.g . impend bowel obstruction ) course study . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment , unless affected area remove surgically . Significant disease , investigator 's opinion would exclude patient study . Patients seizure epileptic disorder condition require medication phenytoin , carbamazepin , phenobarbital . Patients require longterm cortisone therapy . Patients require oral anticoagulation treatment ( marcoumar ) . Known alcohol drug abuse . Medical psychological condition would permit patient complete study sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>mCRC</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>sunitinib</keyword>
	<keyword>DCE-MRI</keyword>
	<keyword>DCE-USI</keyword>
</DOC>